Author(s):
De Marchi, Pedro ; Melendez, Matias E. ; Laus, Ana C. ; Kuhlmann, Pamela A. ; de Carvalho, Ana Carolina ; Arantes, Lidia Maria R.B. ; Evangelista, Adriane F. ; Andrade, Edilene S. ; de Castro, Gilberto ; Reis, Rui M. ; Carvalho, André Lopes ; de Souza Viana, Luciano
Date: 2022
Persistent ID: http://hdl.handle.net/11449/221365
Origin: Oasisbr
Subject(s): Head and neck cancer; Induction chemotherapy; LAHNSCC; Pharmacogenomic; SNP; Toxicity
Description
Made available in DSpace on 2022-04-28T19:27:47Z (GMT). No. of bitstreams: 0 Previous issue date: 2019-11-01
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Background: Induction chemotherapy in locally-advanced head and neck squamous cell carcinoma (LAHNSCC) patients is potentially associated to serious adverse events. Biomarkers associated with toxicity could tailor its indication. This study evaluated the association between single-nucleotide polymorphisms (SNPs) in metabolic genes and toxicity to induction chemotherapy. Methods: 59 LAHNSCC phase II clinical trial patients (NCT00959387) were assessed regarding 47 metabolic genes (366 SNPs). Toxicities were graded (CTCAE 3.0) and statistical analysis was performed. Results: The SNPs rs8187710 (ABCC2) and rs1801131 (MTHFR) were associated to increased risk of gastrointestinal toxicity, whereas the SNPs rs3788007 (ABCG1) and rs4148943 (CHST3) were associated to decreased risk. Two other SNPs, rs2301159 (SLC10A2) and rs2470890 (CYP1A2), were associated with increased risk of hematological toxicity. Nevertheless, these SNPs did not remain significant after adjusting for multiple comparisons. Conclusions: This study could not demonstrate relationship between SNPs and toxicity to induction chemotherapy in LAHNSCC patients. The small number of patients may have affected the results.
Department of Medical Oncology Barretos Cancer Hospital
Molecular Oncology Research Center Barretos Cancer Hospital
Department of Head and Neck Surgery Barretos Cancer Hospital
Universidade do Estado de São Paulo
CNPq: 473210/2012-6